COA-APTIC Caregiver Concept Elicitation Study
1 other identifier
observational
44
1 country
1
Brief Summary
This is a concept elicitation study to identify important aspects of pain assessment, treatment, and response to treatment in children under than 3 years of age from a caregiver's perspective.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jun 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 14, 2020
CompletedFirst Posted
Study publicly available on registry
May 18, 2020
CompletedStudy Start
First participant enrolled
June 23, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 26, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
April 26, 2022
CompletedJune 9, 2022
August 1, 2021
10 months
May 14, 2020
June 7, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Caregiver perspective on how to identify or recognize pain in children 0 to <3 years old.
A 1-hour qualitative interview will be conducted and transcript or interviewer notes will be coded to assess how caregivers identify and recognize acute pain in infants and young children.
1 hour
Caregiver perspective on how and when to intervene for acute pain in children 0 to <3 years old.
A 1-hour qualitative interview will be conducted and transcript or interviewer notes will be coded to assess caregiver's perspective on how and when to treat acute pain in infants and young children.
1 hour
Caregiver perspective on how to evaluate response to treatment for acute pain in children 0 to <3 years old.
A 1-hour qualitative interview will be conducted and transcript or interviewer notes will be coded to assess how caregivers evaluate response to treatment for acute pain in infants and young children.
1 hour
Caregiver perspective on important side effects of acute pain therapeutics in children 0 to <3 years old.
A 1-hour qualitative interview will be conducted and transcript or interviewer notes will be coded to assess caregiver's perspective on important side effects of acute pain in infants and young children.
1 hour
Study Arms (1)
Caregivers
Caregivers who care for a child that is both under 3 years of age and has experienced acute pain. This cohort will participate in a qualitative interview about pain assessment, treatment, and response to treatment in their child.
Interventions
There is no intervention as part of this study. Caregivers will participate in a qualitative interview over the phone or by video.
Eligibility Criteria
The study population will be caregivers of children 0 to \<3 years old who have experienced acute pain. Eligible caregivers will be identified by Pediatric Trials Network sites across the United States. Eligible participants will be identified through recruitment for a pre-existing Pediatric Trials Network study called Pharmacokinetics and Safety of Anesthetics and Analgesics in Children and Adolescents.
You may qualify if:
- Cares for a child who is both:
- Between 0 and \<3 years of age
- Experiencing or has experienced acute pain in one of the following categories:
- Malignant or non-malignant visceral or hematologic disease
- Surgery (or other procedure)
- Trauma or injury
- Congenital conditions
- Is over the age of 18 years old.
- Can speak and understand English.
- Is capable of and willing to provide informed consent for interview participation and to collect medical data from the child's medical record.
You may not qualify if:
- Lack of access to a telephone or computer for interview
- Has a child with acute pain that is extremely premature (less than 32 weeks gestation at the time of enrollment) and no other eligible child.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Duke Universitylead
- Food and Drug Administration (FDA)collaborator
Study Sites (1)
Duke University
Durham, North Carolina, 27701, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bryce Reeve, PhD
Duke University
- PRINCIPAL INVESTIGATOR
Kanecia Zimmerman, MD, MPH
Duke University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 14, 2020
First Posted
May 18, 2020
Study Start
June 23, 2021
Primary Completion
April 26, 2022
Study Completion
April 26, 2022
Last Updated
June 9, 2022
Record last verified: 2021-08
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared outside of the study team.